# EDGAR Filing Document

**Accession Number:** 0001752059
**File Stem:** 0001193125-26-159757
**Filing Date:** 2026-4
**Character Count:** 5073
**Document Hash:** 0671546bcbd5abc53176d59f37e6bf54
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-159757.hdr.sgml**: 20260416

**ACCESSION NUMBER**: 0001193125-26-159757

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260416

**FILED AS OF DATE**: 20260416

**DATE AS OF CHANGE**: 20260416

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kaplan Andrew T.
- **CENTRAL INDEX KEY:** 0001752059

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43233
- **FILM NUMBER:** 26869049

**MAIL ADDRESS:**
- **STREET 1:** C/O BAIN CAPITAL PRIVATE EQUITY, LP
- **STREET 2:** 200 CLARENDON STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kailera Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002096997
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 180 THIRD AVENUE
- **STREET 2:** 4TH FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 508-440-9475

**MAIL ADDRESS:**
- **STREET 1:** 180 THIRD AVENUE
- **STREET 2:** 4TH FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kaplan Andrew T.<br><sub>(Last) (First) (Middle)</sub><br>C/O BAIN CAPITAL INVESTORS LLC<br>200 CLARENDON STREET<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Kailera Therapeutics, Inc. [ KLRA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-04-16 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series B Preferred Stock | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 17857143 | $0 | I | See footnotes<sup>(2)(3)</sup> |

---

### Footnotes:

(1) Each share of the Issuer's Series B Preferred Stock is convertible, at the option of the holder, into shares of the Issuer's Common Stock on a 1:1 basis and will automatically convert upon the closing of the Issuer's initial public offering. These securities have no expiration date.

(2) Represents shares of the Issuer's Series B Preferred Stock held directly by BCPE Perseus Investor, LP ("BCPE Perseus").

(3) Mr. Kaplan is a Partner of Bain Capital Investors, LLC ("BCI"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

**Signature:** /s/ Andrew Kaplan  
**Date:** 2026-04-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**